Merck (NYSE: MRK) announced that its Phase 3 KEYNOTE-B96 trial met its secondary endpoint of overall survival for patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE